# 2 alpha Methyl dopaminimino 6,7 dihydroxy 1,2,3,4 tetrahydronaphthalene, its salts, and a process for preparation thereof.

## Abstract
Derivatives of 2 amino 6,7 dihydroxytetrahydronaph thalene ADTN represented by the formula These derivatives of 2 amino 6,7 dihydroxytetrahydro naphthalene are useful as inotropes. The compounds may be prepared by reductive amina tion of the protected 2 amino 6,7 dihydroxytetrahydro naphthalene.

## Claims
WE CLAIM 1. A compound of the formulaEMI12.1 wherein R is OH, an alkyloxy, hydroxyalkyl, or an acyloxy and R is an arylalkyl where the aryl group is benzyl, substituted benzyl, phenyl or substituted phenyl and the alkyl group is a straight or branched chain alkyl having one to twenty carbon atoms and the pharmaceutically acceptable salts thereof. 2. A compound according to claim i, wherein R is OH, and R is an arylalkyl of the formulaEMI12.2 3. A compound according to claim 1, wherein tetrahydronaphthalene is OCH3, and R is an arylalkyl of the formulaEMI12.3 4. A compound according to claim 1, wherein R is acetyloxy andR is an arylalkyl of the formulaEMI13.1 5. A compound according to claim 1, wherein R is OH and R is an arylalkyl of the formulaEMI13.2 6. A compound according to claim 1, wherein R is OH and R is an arylalkyl of the formulaEMI13.3 7. A compound according to claim 1, wherein R is OCH3 and R is an arylalkyl of the formulaEMI13.4

## Description
DERIVATIVES OF 2 AMINO 6,7 DIHYDROXYTETRAHYDRO NAPHTHALENE ADTN DETAILED DESCRIPTICN OF THE INVENTION This invention relates to derivatives of 2 amino 6,7 dihydroxytetrahydronaphthalene ADTN and, more particularly, toN arylalkyl derivatives of 2 amino 6,7 dihydroxytetrahydro naphthalene ADTN characterized by formula I EMI1.1 wherein R is OH, alkyloxy, hydroxyalkyl or acyloxy, and R is an arylalkyl where the aryl group is benzyl, substituted benzyl, phenyl or substituted phenyl and the alkyl group is a straight or branched chain alkyl having one to twenty carbon atoms and the pharnaceutically acceptable salts thereof. The term alkyloxy as used herein refers to oxygenated straight or branched chain radicals containing one to ten carbon atoms, as illustrated by, but not limited to, methoxy, ethoxy, butoxy and the like. The term hydroxyalkyl as used herein refers to hydroxylated straight or branched chain radicals containing one to ten carbon atoms, as illustrated by, but not limited to 2 propanol, 3 propanol and the like. The term aryl as used herein refers to benzyl, substituted benzyl, phenyl and substituted phenyl where the substituents of benzyl and phenyl include loweralkyl, hydroxy, alkoxy, acyloxy and the like. The term alkyl refers to straight and branched chain alkyl radicals having from one to twenty carbon atoms such as methyl, n amyl, 3 methyl 2 octyl, 2 nonyl and 2 tetradecyl. The term acyloxy as used herein refers to acetoxy, propionyloxy, butyryloxy and the like. The term pharmaceutically acceptable salts refers to acid audi tioji salts prepared by reacting the bdsic amines of this invention with an organic or inorganic acid, or by reacting the amine salts with the salt of an appropriate acid. Representative salts which are so formed include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oleate, laurate, benzoate, phosphate, citrate, maleate, succinate, tartrate and napsylate salts of the gamines. The present compounds, i.e., N arylalkyl derivatives of 2 amino 6,7 dihydroxytetrahydronaphthalene ADTN , may be prepared by reductive aminations of the protected ADTN which may be prepared by a modification of the preparation reported by J. G.Cannon et al. J. Med. Chem., 20, p. 1111 1977 and as illustrated in Scheme I below. Scheme I EMI3.1 The preparation of the present derivatives by reductive aminations of the protected ADTN is carried out with the appropriate ketones and aldehydes. Generally, in the preDaration of the present derivatives.there is, initially, a solution of 2 amino 6,7 dimethoxy 1,2,3,4tetrahydronaphthalene VI in dry methanol is treated with the appropriate ketone or aldehyde and NaCNBH3 under a nitrogen atmosphere. The mixture is then stirred for 72 hours whereupon concentrated HCl is added dropwise until the mixture becomes acidic. The methanol is removed on a rotary evaporator and the mixture is extracted with ether. The aqueous mixture is made basic to a pH greater than 12.0 with solid KOH and the mixture is extracted with ether. The combined extracts are dried MgSO4 and the solvent is removed on a rotary evaporator. The products are dissolved in CHCl3 and hydrogen chloride is bubbled in and the solvent removed on a rotary evaporator. The products are crystallized in isopropanol and then isolated. The compounds of the present invention that can be prepared by the reductive aminations of the protected ADTN and represented by formula I include EMI4.1 a 2 3 p hydroxyphenyl 1 methylpropyl amino 6,7 dihy droxy 1,2,3,4 tetrahydronaphthalene where R is OH and R is represented by the formulaEMI4.2 b 2 3 p hydroxyphenyl 1 methylpropyl amino 6,7 dime thoxy 1,2,3,4 tetrahydronaphthalene where R is OCH3 and R is represented by the formulaEMI5.1 c 2 diacetoxy a methyl dopaminimino 6,7 diacetoxy 1,2, 3,4 tetrahydronaphthalene where R is CH3CO and R is represented by the formulaEMI5.2 d 2 a methyl dopaminimino 6,7 dihydroxy 1,2,3,4 tetra hydronaphthalene where R is OH and R is represented by the formulaEMI5.3 e RTI ID 5.3 2 Dopaminimino 6,7 dihydroxy 1,2,3,4 tetrahydronaph thalene where R is OH and R is represented by the formulaEMI5.4 f 2 dimethoxy a methyl dopaminimino 6,7 dimethoxy 1,2, 3,4 tetrahydronaphthalene where R is OCH3 and R is represented by the formulaEMI6.1 The compounds of the present invention exhibit inotropic activity in warm blooded animals at a dosage ranging from about 10.0 ug kg to about 60.0 ug kg of the body weight daily. The following examples will further illustrate the present invention. EXAMPLE I Preparation of 6,7 dimethoxy 2 methoxyimino 1,2,3,4 tetrahydronaphthalene V A mixture of 0.56 g 6.7 mmol of methoxylamine hydrochlo ride and 6.5 ml 6.5 mmol of a 1M aqueous solution of NaOH was added to 0.689 g 3.34 mmol of 6,7 dimethoxy 2 tetralone IV . While under a nitrogen atmosphere the mixture was warmed to ca..1000 for 15 minutes and then kept at 400 using an infrared lamp for 18 hours. Water was added to the mixture which was then extracted with ether. The combined extracts were dried MgS04 and the solvent was removed on a rotary evaporator, affording 0.700 9 89.2 of brown oil nmr CDcl3 6 2.3 2.9 m, 4H , 3.32 S, 1H , 3.57 S, 1H , 3.73 S, 6H , 3.78 S, 3H , 6.4 6.6 m, 2H . The compound was used without further purification. EXAMPLE II Preparation of 2 amino 6,7 dimethoxy 1,2,3,4 tetrahydronaphthalene VI 2 amino 6s7 dimethoxy 1,2,3,4 tetrahydronaphthalene VI . A solution of 0.700 g 2.98 mmol of V in 20 ml of dry THF was treated with 5.0 ml 5.0 mmol of a 1M borane THF solution while under a nitrogen atmosphere. The solution was heated to reflux for 6 hours and was then quenched with water. The aqueous mixture was extracted with CHCl3, the combined extracts were dried and hydrogen chloride was bubbled into the solution. The solvent was removed on a rotary evaporator, leaving 0.775 g of off white solid. Crystallization from isopropanol afforded 0.469 g 64.8 of off white product mp. 83 860C lit. 85 870C . EXAMPLE III Preparation of ADTN Derivatives by Reductive Amination of Protected ADTN In the preparation of the derivatives, the general procedure was as follows A solution of 1 mmol of VI in 2 ml of dry methanol was treated with 1 mmol of the appropriate ketone or aldehyde and 1.05 mmol of NaCNBH3 under a nitrogen atmosphere. The mixture was stirred for 72 hours whereupon concentrated HCl was added dropwise until the mixture became acidic. The methanol was removed on a rotary evaporator, the mixture was extracted with ether. The aqueous mixture was made basic pH . 12 with solid KOH and the mixture was extracted with ether. The combined extracts were dried MgS04 and the solvent was removed on a rotary evaporator. The products were dissolved in CHCl3, hydrogen chloride was bubbled in and the solvent was removed on a rotary evaporator.Crystallization of the products was carried out in isopropanol and the compounds were isolated. The compounds produced and the date of their preparation are as follows a 2 3 p hydroxyphenyl 1 methylpropyl amino 6,7 dihy droxy 1,2,3,4 tetrahydronaphthalene The compound was isolated in 43 yield mp. 236 2370C, nmr CD3OD 6 1.3 1.7 m, 3H , 1.7 3.8 m, 12H , 6.43 S, 2H , 6.65 d, J 7Hz, 2H , 7.00 d, J 7 Hz, 2H . Calcd for C20H26NO3Br C, 58.63 H, 6.42 N, 3.43. Found C, 58.54 H, 6.39 N, 3.37. b 2 3 p hydroxyphenyl 1 methylpropyl amino 6,7 dime thoxy 1,2,3,4 tetrahydronaphthalene The compound was isolated in 91 yield mp. 230 2320C d nmr CDCl3 6 1.13 d, J 6 Hz, 3H , 1.3 2.2 m, 4H , 2.2 3.2 m, 8H , 3.73 S, 6H , 4.82 S, 2H , 6.47 m, 2H , 6.75 m, 4H, J 8 Hz . Calcd for C22H30N03Cl C, 67.41 H, 7.46 N, 3.57. Found C, 67.18 H, 7.72 N, 3.46. c 2 diacetoxy a methyl dopaminimino 6,7 diacetoxy 1, 2,3,4 tetrahydronaphthalene A solution of 0.200 g of 2 a methyl dopaminimino 6,7 dihydroxy 1,2,3,4 tetrahydronaphthalene d in 1 ml of trifluoroacetic acid and 1 ml of acetyl chloride was warmed to ca. 800 for 0.5 h. The solvent was evaporated and crystallization of the solid from ethanol afforded 0.140 g 50.44 of product mp. 192 194 C nmr CD3OD 6 1.15 d, J 6 Hz, 3H , 2.10 S, 12H , 2.6 3.9 m, 10H , 6.8 6.9 m, 2H , 6 .03 S, 3H . Calcd for C27H32NO8Br C, 56.06 H, 5.58 N, 2.42. Found C, 56.19 H, 5.40 N, 2.26. d 2 a methyl dopaminimino 6,7 dihydroxy 1,2,3,4 tetra hydronaphthalene The compound was isolated in 57 yield. nmr CD3OD 6 1.32, d, J 6 Hz, 3H , 1.5 4.0 m, 10H 6.4 6.8 m, 5H . e 2 dimethoxy a methyl dopaminimino 6,7 dimethoxy 1, 2,3,4 tetrahydronaphthalene The compound was isolated in 35,0 yield mp. 224 229 C ir KBr 3480, 3020 2650, 1612, 1590 cm EXAMPLE IV Inotropic, Chronotropic and Pressor Depressor Activities The following tests were conducted In anesthetized, open chested dogs, instrumented with aWalton Brodie strain gauge to measure cardiac contractile force, a ventricular catheter to measure left ventricular dP dt and an aortic catheter to measure diastolic blood pressure and heart rate. Contractile force and L.V. dP dt are indices of cardiac contractility and provide information on the inotropic state of the heart.The experimental standard drugs are compared by normalizing pressor depressor and heart rate responses to a given inotropic effect. Cardioselective inotropic agents will produce minimal diastolic pressure changes for any given inotropic effect.Likewise, inotropic selective agents will produce minimal heart rate changes for any given inotropic effect. In the data summary below, compounds A F are Compound Name A 2 3 p hydroxyphenyl l methylpropyl amino 6,7 dimethoxy 1 ,2,3,4 tetrahydronaphthalene B 2 3 p hydroxyphenyl 1 methylpropyl amino 6,7 dihydroxy 1 ,2,3,4 tetrahydronaphthalene C 2 amino 6,7 dihydroxy 1,2,3,4 tetrahydro naphthalene D 4 2 3 p hydroxyphenyl 1 methylpropyl amino ethyl 1,2 benzenediol Dobutamine Lilly E 4 2 aminoethyl 1,2 benzenediol Dopamine F 4 1 hydroxy 2 1 methylethyl amino ethyl 1,2 benzenediol Isoproterenol Inotropic Potency means SEM Compound N CF50 CF100 dP dt75 dP dt150 A 1 157.6 333.1 261.8 756.0 B 2 56.3 197.6 125.4 358.6 C 5 44.9 3.3 118.8 34.7 40.4 3.1 75.6 5.8 D 6 1.4 0.2 4.4 0.2 4.0 0.6 E 6 9.1 1.0 19.6 2.7 9.9 0.7 23.7 3.0 F 6 0.04 0.01 0.09 0.02 0.04 t 0.01 0.14 0.05 ug kg required to produce 50 and 100 increase in cardiac contractile force CF and 75 and 150 increase in left ventricular dP dt dP dt . Cardioselectivity means SEM Compound N CF50 CF100 dP dt75 dP dtl50 A 1 17 27 23 40 B 2 13 57 37 75 C 5 31 9 61 10 30 5 51 5 D 6 3 1 4 3 4 1 3 3 E 6 20 6 12 9 20 7 10 8 F 6 6 2 15 2 6 2 16 2 Change in diastolic blood pressure obtained at CF50, CF100, dP dt75, dp dt150 mm Hg . Inotropic Selectivity means SEM Compound N CF50 CF100 dP dt75 dP dt150 A 1 5 14 10 27 B 2 17 15 0 32 C 5 12 9 21 17 12 10 5 8 D 6 3 1 17 5 3 1 13 2 E 6 5 5 12 5 5 6 13 6 F 6 14 2 34 3 14 1 41 5 Change in heart rate obtained at CF50, CF100 dp dt75, dp dt150 BPM .